United States Patent 4,694,007: Trimethrexate Treatment Methods for Toxoplasmosis and P. carinii
US Patent 4,694,007 is a method-use patent centered on administering trimetrexate to treat infections caused by Toxoplasma gondii (“T. gondii”) and Pneumocystis carinii (historically labeled “P. carinii,” now commonly Pneumocystis jirovecii in updated nomenclature). The claims are narrow on drug identity (trimetrexate) and indication (T. gondii and P. carinii infections), but they broaden across routes (oral is claimed), dose range (a specific example dose is claimed), and adjunct therapy (leucovorin combination).
Because the claim set is method-only, the practical landscape is dominated by (1) validity and enforceability of method claims in the US, (2) whether later products and regimens are designed to avoid literal infringement, and (3) whether surrounding prior art blocks the method claims, especially around dosing and folate-antagonist/leucovorin rescue strategies.
What exactly do the claims cover (scope by claim element)?
Claim 1 (core independent claim)
“A method for treating infections of Toxoplasmosis or P. carinii comprising administering to a mammalian host in need of said treatment an amount of trimetrexate effective to treat said Toxoplasmosis or P. carinii.”
Scope drivers
- Activity type: treatment method (not a composition, not a formulation)
- Infection scope: “Toxoplasmosis” and “P. carinii” infections
- Target population: “mammalian host” in need of treatment
- Drug identity: trimetrexate (no alternative antifolate named)
- Key functional limitation: “amount … effective to treat”
Literal infringement posture
- Likely requires: (i) administration of trimetrexate to a mammal, (ii) infection with one of the specified organisms, and (iii) the administered amount is “effective to treat” as practiced.
- “Effective to treat” typically creates a functional dose regimen tether; it can be satisfied by clinically used dosing that is known to treat the infection, but it is also a litigation anchor for enablement and obviousness/anticipation arguments.
Claim 2 (route limitation)
“The method of claim 1 wherein the trimetrexate is administered orally.”
Scope
- Narrows Claim 1 to oral administration.
- This is a route-specific literal infringement hook: an otherwise identical regimen given by IV or other routes would not meet Claim 2 literally, though Claim 1 could still capture other routes (unless other claim elements are designed around).
Claim 3 (specific dose example)
“The method of claim 1 wherein the trimetrexate is administered in a dosage of about 30 mg/kg.”
Scope
- Narrows Claim 1 to a dose magnitude: about 30 mg/kg.
- “About” introduces tolerance and factual debate on equivalence: dosing near 30 mg/kg can still fall within the claim scope, depending on prosecution history and how “about” is construed.
Claim 4 (combination therapy)
“The method of claim 1 wherein the trimetrexate is administered in combination with leucovorin.”
Scope
- Requires trimetrexate plus leucovorin.
- This is a practical regimen hook because leucovorin is commonly used as a folate rescue strategy in antifolate regimens, and it often becomes a focal point in prior art mapping.
Claim 5 (mechanistic variant)
“A method of inhibiting dihydrofolate reductase production by T. gondii or P. carinii in a mammalian host comprising administering … trimetrexate … effective to inhibit said dihydrofolate reductase production.”
Scope
- Keeps drug and organism limitations but shifts the claim’s functional target from “treating” to inhibiting dihydrofolate reductase (DHFR) production in the organisms within a mammalian host.
- Mechanism-based claims can be litigated on whether the treatment effect necessarily includes the claimed mechanistic activity, and whether later regimens still meet the “inhibit DHFR production” functional limitation.
Key difference from Claim 1
- Claim 1 is clinical outcome defined.
- Claim 5 is biological mechanism defined (DHFR production inhibition), which can broaden or narrow depending on evidence that trimetrexate inhibits DHFR expression/production in the claimed contexts.
How broad is the patent in practice? (route, dose, and adjunct coverage)
Coverage matrix by claim
| Dimension |
Claim 1 |
Claim 2 |
Claim 3 |
Claim 4 |
Claim 5 |
| Organism |
Toxoplasmosis; P. carinii |
same |
same |
same |
T. gondii; P. carinii |
| Drug |
trimetrexate |
trimetrexate |
trimetrexate |
trimetrexate |
trimetrexate |
| Mammalian host |
yes |
yes |
yes |
yes |
yes |
| Outcome/Mechanism |
“effective to treat” |
same |
same |
same |
“inhibiting DHFR production” |
| Route |
not limited |
oral required |
not limited |
not limited |
not limited |
| Dose |
not fixed |
not fixed |
about 30 mg/kg required |
not fixed |
not fixed |
| Leucovorin |
not required |
not required |
not required |
required |
not required |
Net effect
- The patent’s strongest enforcement position is Claim 1 because it is not limited by route, dose magnitude, or adjunct therapy.
- Claims 2-4 create narrower lanes (oral administration, specific dose, leucovorin combination) that can be used to target specific clinical protocols.
- Claim 5 provides a mechanistic angle that may matter for disputes about whether a regimen’s therapeutic effect is the result of claimed DHFR production inhibition.
What would constitute infringement under these claims (and where can design-arounds land)?
Likely literal infringement fact pattern
A US provider or sponsor would be exposed where they administer trimetrexate to a mammalian host with Toxoplasma infection or P. carinii infection and the amount is effective to treat. If they use an oral route, about 30 mg/kg, or pair with leucovorin, Claims 2-4 also become available.
Practical design-around options (claim element avoidance)
Because the claims are method-use and are drug-identity strict, the main avoidance levers are:
- Use a different antifolate or mechanism agent instead of trimetrexate.
- Avoid using trimetrexate in the claimed infection context (hard to do if the clinical indication is targeted).
- Avoid the claimed dosing (for Claim 3) by using regimens that are demonstrably outside “about 30 mg/kg” as construed.
- Avoid leucovorin co-administration (to fall outside Claim 4).
- Use a non-oral route to avoid Claim 2, but Claim 1 still remains.
Mechanism-based avoidance for Claim 5 is more difficult because any regimen that treats and involves DHFR inhibition may still satisfy the functional mechanistic limitation unless clear evidence shows lack of inhibition of DHFR production as claimed.
How does the patent fit into the historical antifolate and folate-rescue landscape?
These claims sit in a class of antifolate regimens where DHFR inhibition is the pharmacologic centerpiece and where folate rescue (often leucovorin) is a standard tolerability strategy. The patent ties trimetrexate to:
- Toxoplasmosis/Pneumocystis infections
- DHFR production inhibition (Claim 5)
- Leucovorin combination (Claim 4)
- Oral dosing (Claim 2)
- A specific dose magnitude (Claim 3)
Implications for freedom-to-operate (FTO)
For an R&D team considering new formulations, dosing regimens, or combination therapies:
- If the product uses trimetrexate and targets the same organisms, the risk is high for method infringement.
- If the plan uses trimetrexate but with different route/dose/adjunct, risk becomes a function of which dependent claim elements are still satisfied and how broadly Claim 1 is applied to the new regimen.
- If the plan uses trimetrexate only for off-target or non-claimed infection types, then the organism-specific limitation becomes the key boundary.
What are the main patentability and validity pressure points (based on claim structure)?
Without prosecution history or the full prior-art file contents, the strongest inference from claim structure is how a challenger would attack it:
1) Anticipation or obviousness targeting
- Drug + indication pairing: If trimetrexate use against toxoplasmosis and/or pneumocystis was known, Claim 1’s “administering trimetrexate effective to treat” can be threatened.
- Leucovorin rescue: If leucovorin combinations were known in antifolate regimens for similar infections, Claim 4 is at higher risk.
- Oral administration: If oral trimetrexate was already used for the same infections, Claim 2 can face validity pressure.
- Specific dose: Claim 3 depends on whether the “about 30 mg/kg” regimen was previously disclosed or would have been routine optimization.
2) Claim indefiniteness and functional scope
- Terms like “effective to treat” and “effective to inhibit DHFR production” are standard claim language but are contested when the record lacks clear support tying the claimed functional outcomes to the specified conditions.
- For mechanism claims (Claim 5), challengers often argue that the claim is not supported by a clear showing of the claimed mechanistic effect at the relevant in vivo levels in the host.
US enforcement and landscape mechanics (method-use patents)
Method claims in the US typically require evidence of actual performance of the claimed steps. For healthcare product makers and prescribers:
- Enforcement tends to focus on clinical practice that matches the claim elements.
- Publicly available prescribing information and clinical trial protocols become relevant because they can show route, dose, and adjunct use.
In practice, the most actionable question is not whether the method is “medically reasonable” but whether the regimen in question is marketed or practiced in a way that matches:
- trimetrexate administration
- the specified infection organisms
- the effective treatment dose
- and any dependent features (oral, about 30 mg/kg, leucovorin).
Claim-by-claim landscape impact for R&D decisions
If the candidate program uses trimetrexate (same organisms)
- High infringement exposure on Claim 1 as soon as the program administers trimetrexate effective to treat toxoplasmosis or P. carinii infections.
- Dependent claims add incremental hooks:
- oral regimens implicate Claim 2
- leucovorin co-therapy implicates Claim 4
- regimens near 30 mg/kg implicate Claim 3
If the program uses trimetrexate but changes regimen components
- Dose changes: Claim 3’s “about 30 mg/kg” creates a moving boundary; even if outside a target dose, a court may find “about” still encompasses the new range.
- Leucovorin omission: removes Claim 4, but does not remove Claim 1.
- Oral to IV switch: removes Claim 2, but does not remove Claim 1.
If the program replaces trimetrexate
- This is the primary clean boundary against the drug-identity limitation.
- Switching to a different antifolate changes the infringement question because the claims require “trimetrexate.”
Key Takeaways
- US 4,694,007 is a method-of-treatment patent requiring trimetrexate administration to a mammalian host with Toxoplasma or P. carinii infection (Claim 1).
- The patent’s enforceable lanes expand with route (oral) (Claim 2), dose magnitude (about 30 mg/kg) (Claim 3), leucovorin combination (Claim 4), and a mechanistic DHFR production inhibition limitation (Claim 5).
- For freedom-to-operate, the central risk is that any trimetrexate regimen used to treat the claimed infections can fall under Claim 1 regardless of route, dose, or leucovorin presence.
FAQs
-
Is this patent about trimetrexate formulations or treatment methods?
It is a treatment method patent: the claims require administering trimetrexate, not claiming a specific composition or formulation.
-
Which claim is the most broadly applicable?
Claim 1 is the broadest because it requires trimetrexate administration effective to treat the specified infections without route, dose, or leucovorin limitations.
-
Does oral dosing increase infringement risk?
Yes. Claim 2 specifically covers oral administration of trimetrexate under the Claim 1 treatment framework.
-
Does combining with leucovorin matter for infringement?
Yes. Claim 4 adds leucovorin co-administration as a required limitation, creating an additional infringement lane beyond Claim 1.
-
What does Claim 5 add beyond “treating”?
Claim 5 adds a mechanistic requirement: inhibition of dihydrofolate reductase production by the specified organisms in the mammalian host.
References
[1] US Patent 4,694,007.
